1-Octacosanol.
Research-backed compound with potential health benefits. Supposed to lower LDL cholesterol and improve exercise performance. Early studies were promising, but dozens of better, independent trials showed it doesn't really work for either.
Reviewed March 2026
- Category
- Compound
What 1-Octacosanol is, and what it does.
- Does it work
- No. And that's being generous. The science just isn't there. The positive results from one lab couldn't be repeated by anyone else. This is a classic case of initial hype not holding up.
- How much to take
- Studies used 5-20 mg daily. But since it's not effective, the best dose is zero.
- Time to feel it
- Nothing registers day to day. Where researchers looked for change, they read it on a lipid panel after six to eight weeks rather than in how people felt.
- The first dose
- Zero. You won't feel a thing. This isn't a stimulant or a relaxant.
- With regular use
- You'll be lighter in the wallet. There's no credible evidence it improves cholesterol or health markers in the long run.
- How well tolerated
- Seems well tolerated. The biggest side effect is disappointment when your lab results don't change.
- How it feels
- Like taking a sugar pill. There is no sensation, no kick-in, and no noticeable effect on your body or mind.
- The overlooked benefit
- It's a 28-carbon wax alcohol, effectively insoluble in water, so a meal containing fat is what carries any of it across the gut wall. Dry and fasted, very little goes anywhere.
5 to 20mg a day is where 1-Octacosanol works.
Source: Taylor et al. Lipids 2003; Examine.com Policosanol page
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
1-Octacosanol is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- cholesterol already in the normal rangeMeta-analysis
- endurance and reaction time during exerciseRandomised trial
- platelet aggregation measuresRandomised trial
- lipid metabolism in animal modelsAnimal study
- very long chain fatty alcohol oxidation through peroxisomal beta-oxidationNarrative review
Questions people ask about 1-Octacosanol.
- Is this better than a statin for cholesterol?
- Not even in the same league. Statins are proven, life-saving drugs. The evidence says this is an ineffective supplement.
- What's the difference between policosanol and octacosanol?
- Octacosanol is the main active ingredient in policosanol. Think of policosanol as the whole plant extract and octacosanol as the specific compound they isolated from it.
- Does it help with endurance or athletic performance?
- Early claims suggested it might, but more rigorous, independent research showed no benefit for athletes. It won't help your workout.
- Why was it so popular then?
- Almost all the positive research came from a single research group in Cuba in the 1990s. When other independent labs tried to replicate their amazing results, they couldn't.
- Are there any side effects?
- Extremely rare and mild, like headache or upset stomach. Most people experience nothing at all.
- Should I try it just in case?
- You're better off spending the money on something proven, like fish oil or more vegetables. There are better places to put your money for heart health.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Octacosanol is a 28-carbon fatty alcohol with negligible water solubility, so its absorption depends on incorporation into mixed micelles alongside dietary fat and bile salts. Taking it with a fat-containing meal or a lipid vehicle is what gets any of it across the intestinal wall. Absorption of the intact alcohol is low even then, which is the honest framing.
Phospholipids act as emulsifiers, dispersing a waxy solid into fine droplets that mixed micelles can take up. Formulators add lecithin to policosanol powders for exactly that reason. The step improves dispersion in the gut lumen and is a formulation measure rather than a clinical finding.
Phosphatidylcholine is the principal phospholipid of bile and of the mixed micelle, so it is the physiological carrier a poorly soluble long chain alcohol relies on. Supplying it in the formula supports the same dispersion step from outside. This concerns delivery, not activity.
Plant wax fractions and tocopherols travel together in the lipid phase, and alpha-tocopherol protects the lipid environment that a fatty alcohol partitions into. Formulas combining them keep the lipid fraction stable through shelf life as well. The pairing is compositional and stability-driven.
Plant sterols reduce cholesterol absorption by competing for space in the mixed micelle, while octacosanol has been studied for effects on hepatic lipid handling markers. The two act at different points of the same lipid economy. Both endpoints in the literature are lipid markers, not clinical outcomes.
Viscous soluble fibre binds bile acids and increases their faecal loss, which draws on the hepatic cholesterol pool. Octacosanol has been examined for effects on lipid-regulatory markers such as PCSK9. Different mechanisms, one measured panel, and the pairing has not been trialled as a combination.
Ubiquinone is synthesised through the same mevalonate pathway that produces cholesterol, so anything acting on that pathway touches both. Formulas pairing them are covering that overlap. The rationale is biochemical and no combination study exists.
EPA and DHA lower hepatic triglyceride output largely by reducing very low density lipoprotein assembly, a different lever from the one octacosanol has been examined against. Both are measured on the same lipid panel. Report the endpoints as markers rather than as outcomes.
Once octacosanol is oxidised to its corresponding very long chain fatty acid, that acid is shortened in the peroxisome and then handed to the mitochondrion, where carnitine is required for entry of the resulting acyl groups. Carnitine sits downstream on the disposal route rather than acting on the alcohol itself. This is textbook fatty acid transport.
Lipoic acid is a cofactor for the mitochondrial dehydrogenase complexes that process the acetyl units beta-oxidation produces. A long chain alcohol taken for its effect on lipid handling ends up feeding those same complexes. The link is metabolic and no combination has been tested.
Red yeast rice contains monacolin K, which acts directly on HMG-CoA reductase, whereas octacosanol has been studied against downstream regulatory markers such as PCSK9. Stacking two lipid-directed inputs is something to raise with a clinician rather than assume. The interaction is inferred and not measured for the pair.
Berberine increases LDL receptor expression through a post-transcriptional route, a different lever from the one octacosanol has been examined against. Both show up in lipid-panel work. Any combined effect is a marker change and has not been tested together.
Nothing specific on file for 1-Octacosanol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What 1-Octacosanol actually does.
1-octacosanol is a straight-chain saturated primary fatty alcohol of 28 carbons, solid at room temperature and effectively insoluble in water, which is why its uptake depends on dietary fat and bile-salt mixed micelles.
Policosanol is not a single compound but a mixture of very long chain aliphatic alcohols in which octacosanol predominates, with triacontanol, hexacosanol and dotriacontanol present at lower proportions; the ratio depends on the wax it was made from.
Absorbed fatty alcohols are oxidised by fatty alcohol dehydrogenase and fatty aldehyde dehydrogenase to the corresponding very long chain fatty acid, which is then chain-shortened by peroxisomal beta-oxidation before mitochondrial handling.
Very long chain fatty acids cannot enter the mitochondrion directly and are shortened in the peroxisome first, so the disposal of an octacosanol dose runs through peroxisomal rather than mitochondrial beta-oxidation at the outset.
Where 1-Octacosanol comes from.
Waxes from sugarcane, beeswax or cereal bran are heated with alkali to break them apart, and the fatty alcohols that come loose are washed into a solvent and crystallised out. The result is a white waxy powder whose exact make-up depends on which wax it started from.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
The commonest starting material is the wax recovered from sugarcane processing residue. Beeswax and wheat germ or rice bran wax are the other routes, and each carries a different ratio of chain lengths into the finished material.
The wax is heated with alkali so the ester bonds break, releasing the free long chain alcohols from the fatty acids they were bound to.
The freed alcohols sit in the unsaponifiable fraction and are pulled into an organic solvent, leaving the soap phase behind.
Repeated recrystallisation from solvent raises the alcohol content; separating octacosanol from its close chain-length neighbours takes a further chromatographic or fractional step, since they differ by only a few carbons.
Gas chromatography sets the percentage of each alcohol, and it is that profile rather than a single total number that describes what the material is.
The waxy solid is milled and either dispersed into an oil carrier with an emulsifier or blended onto a powder carrier for tabletting.
Getting 1-Octacosanol from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Octacosanol supplementation changed circulating PCSK9 levels and its relationship with LDL cholesterol in adults with disturbed blood lipids; both endpoints are laboratory markers and neither is a clinical outcome.Randomised trial. Ciric et al., 2021 (Nutrients). PMID 33802219 ↗
- A systematic review and dose-response meta-analysis of randomised trials of policosanol, of which octacosanol is the main component, reported pooled change in serum creatinine; creatinine is a marker of kidney filtration and the analysis is a safety-side measure rather than a benefit claim.Meta-analysis. Amini et al., 2025 (BMC Complementary Medicine and Therapies). PMID 40382621 ↗
- Octacosanol showed cytoprotective effects in a lipopolysaccharide-stimulated inflammatory model, identifying a cell-level mechanism; the finding is laboratory work and not human evidence.In vitro study. Tang et al., 2026 (Frontiers in Immunology). PMID 41756299 ↗
- Fatty acid esterification of octacosanol attenuated triglyceride and cholesterol synthesis measures in mice, indicating that the ester form is handled differently from the free alcohol.Animal study. Kamchonemenukool et al., 2025 (Journal of Agricultural and Food Chemistry). PMID 39808738 ↗
- An oleic acid ester of octacosanol altered lipid-handling measures associated with excess body weight in a preclinical model; the work characterises a modified ingredient rather than the plain alcohol.Animal study. Koh et al., 2026 (Journal of Agricultural and Food Chemistry). PMID 41254832 ↗
- Octacosanol combined with Saccharomyces cerevisiae changed growth and immune-related measures in a farmed aquatic species; the design tests an interaction between the two inputs and is not human evidence.Animal study. Shehata et al., 2026 (Developmental and Comparative Immunology). PMID 42203038 ↗
- A systematic review of dietary supplements used in taekwondo names octacosanol among the ergogenic ingredients covered and reports the evidence for the class as limited in volume.Systematic review. Shu et al., 2025 (Life). PMID 40283114 ↗
These are the studies our verdict leans on, chosen from the 7 we read for 1-Octacosanol. The full linked list is below.
The studies, linked.
1 source behind our 1-Octacosanol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialSafety and Efficacy of Policosanol Monotherapy and When Added to Chronic Statin Therapy: A Pilot StudyClinicalTrials.gov ↗NA · 54 participants · Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.